 Interleukin-1
"Interleukin-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.
| Descriptor ID |
D007375
|
| MeSH Number(s) |
D12.644.276.374.465.010 D12.644.276.374.500.400 D12.776.467.374.465.010 D12.776.467.374.500.400 D23.529.374.465.131 D23.529.374.500.400
|
| Concept/Terms |
Interleukin-1- Interleukin-1
- Interleukin 1
- IL-1
- T Helper Factor
- Lymphocyte-Activating Factor
- Lymphocyte Activating Factor
- Macrophage Cell Factor
- Epidermal Cell Derived Thymocyte-Activating Factor
- Epidermal Cell Derived Thymocyte Activating Factor
- Interleukin I
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-1".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-1".
This graph shows the total number of publications written about "Interleukin-1" by people in this website by year, and whether "Interleukin-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 26 | 6 | 32 | | 1992 | 27 | 11 | 38 | | 1993 | 27 | 13 | 40 | | 1994 | 36 | 7 | 43 | | 1995 | 20 | 13 | 33 | | 1996 | 15 | 8 | 23 | | 1997 | 16 | 6 | 22 | | 1998 | 19 | 8 | 27 | | 1999 | 19 | 10 | 29 | | 2000 | 19 | 10 | 29 | | 2001 | 12 | 10 | 22 | | 2002 | 5 | 14 | 19 | | 2003 | 12 | 9 | 21 | | 2004 | 18 | 10 | 28 | | 2005 | 8 | 9 | 17 | | 2006 | 7 | 6 | 13 | | 2007 | 3 | 1 | 4 | | 2008 | 1 | 2 | 3 | | 2009 | 6 | 2 | 8 | | 2010 | 7 | 5 | 12 | | 2011 | 5 | 4 | 9 | | 2012 | 2 | 5 | 7 | | 2013 | 5 | 3 | 8 | | 2014 | 8 | 2 | 10 | | 2015 | 10 | 3 | 13 | | 2016 | 8 | 1 | 9 | | 2017 | 9 | 1 | 10 | | 2018 | 6 | 2 | 8 | | 2019 | 10 | 3 | 13 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-1" by people in Profiles.
-
Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020 04 24; 126(9):1260-1280.
-
Klück V, van Deuren RC, Cavalli G, Shaukat A, Arts P, Cleophas MC, Cri?an TO, Tausche AK, Riches P, Dalbeth N, Stamp LK, Hindmarsh JH, Jansen TLTA, Janssen M, Steehouwer M, Lelieveld S, van de Vorst M, Gilissen C, Dagna L, Van de Veerdonk FL, Eisenmesser EZ, Kim S, Merriman TR, Hoischen A, Netea MG, Dinarello CA, Joosten LA. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Ann Rheum Dis. 2020 04; 79(4):536-544.
-
Rabe JL, Hernandez G, Chavez JS, Mills TS, Nerlov C, Pietras EM. CD34 and EPCR coordinately enrich functional murine hematopoietic stem cells under normal and inflammatory conditions. Exp Hematol. 2020 01; 81:1-15.e6.
-
Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK, Skerra A, Dinarello CA. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. J Biol Chem. 2020 01 17; 295(3):868-882.
-
Ballak DB, Brunt VE, Sapinsley ZJ, Ziemba BP, Richey JJ, Zigler MC, Johnson LC, Gioscia-Ryan RA, Culp-Hill R, Eisenmesser EZ, D'Alessandro A, Dinarello CA, Seals DR. Short-term interleukin-37 treatment improves vascular endothelial function, endurance exercise capacity, and whole-body glucose metabolism in old mice. Aging Cell. 2020 01; 19(1):e13074.
-
Mountford S, Ringleb A, Schwaiger R, Mayr D, Kobold S, Dinarello CA, Bufler P. Interleukin-37 Inhibits Colon Carcinogensis During Chronic Colitis. Front Immunol. 2019; 10:2632.
-
Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019 10; 15(10):612-632.
-
Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol. 2019 12; 19(12):734-746.
-
Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M, Beckman K, Fujita M, Fischer S, Dinarello CA. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019 09; 20(9):1138-1149.
-
Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int J Mol Sci. 2019 Jul 05; 20(13).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|